Skip to content
primarysourced Photonics sector GF
GFS
~8 min read · 1,884 words ·updated 2026-04-29 · confidence 41%

Capex cycle — fabs, CHIPS Act, AMITC tax credit

As of: 2026-04-29 (data through FY2025 20-F filed 2026-02-27)

Reference: Capex figures reconcile to FY25 20-F MD&A “Investing Activities” line items and Note disclosures. CHIPS / state-incentive figures cite original 8-K-equivalent press releases referenced in the 20-F.

Confidence legend: ✓ verified-primary 20-F · ◐ aggregator / press release · ⚠ inferred / estimate

1. Capex history — five-year trail

YearCapex ($M)YoY $ΔYoY %ΔCapex / RevenueNotes
2021~1,800 ⚠——n/dIPO year; pre-IPO scale-up
2022~3,100 ⚠+1,300+72%n/dPeak — Fab 8 expansion + Dresden Module 2 + Singapore additions
20231,804 ✓−1,300−42%24.4%Cycle taper; FY23 revenue $7,392M
2024625 ✓−1,179−65%9.3%Trough — capex discipline + Q4 impairment ($935M) reset
2025722 ✓+97+16%10.6%Modest re-investment

FY25 verbatim (20-F MD&A): “Our capital expenditures including purchases of property, plant and equipment, intangible assets and capitalized development costs for the years ended December 31, 2025, 2024 and 2023 amounted to $722 million, $625 million and $1.804 billion, respectively.”

FY25 cash-flow statement detail (Investing Activities):

  • Purchases of PP&E + intangibles: $(722)M
  • Acquisitions, net of cash: $(682)M
  • Proceeds from government grants: $148M
  • Proceeds from sale of PP&E: $170M (incl. tool sales)
  • Net purchases of marketable securities: $(128)M (= $(1,618)M purchases + $292M sales + $1,198M maturities)
  • Purchases of equity securities: $(59)M

Net cash used in investing activities FY25: $(1,274)M (vs. $(1,125)M FY24).

Interpretation. GFS is in the late-stage of a capacity buildout cycle. The 2022 peak ($3.1B est.) corresponded to the post-IPO surge to lock in capacity for LTA-supported demand. 2023 saw rapid taper, 2024 was a trough with the Q4 impairment formally writing off ~$935M of legacy production capacity at Malta. 2025 is a modest re-investment year as the company pivots toward AI-driven datacenter capacity (Fotonix expansion, advanced packaging at Fab 8) and integrates the AMF Singapore acquisition.

2. Fab footprint and capex allocation (qualitative)

2.1 Malta, NY — Fab 8 (300mm)

The flagship facility and the locus of the CHIPS Direct Funding Agreement. Process portfolio: 12LP/12LP+, 22FDX, 14LPP, RF SOI variants, 45CLO 9WG silicon photonics (Fotonix). Capacity expansion underway:

  • Existing Fab 8 expansion (capacity uplift)
  • New “state-of-the-art” fab on the Fab 8 campus (greenfield)
  • Advanced packaging and testing center (Jan 2025 add-on, $75M of CHIPS funding)

Per FY25 20-F: “In 2025, we received funding for the achievement of the first two milestones for the expansion of the Fab 8 facility.” Milestones include capex execution, process technology development, and facility completion thresholds.

The Fab 8 Q4’24 impairment of $935M was specifically about “legacy investments in production capacity at its fabrication facility in Malta, New York” — i.e., older equipment generations being depreciated to recoverable value. The new expansion is on the upper-edge advanced-process side of Fab 8 (45nm SiPh, 22FDX) — different equipment class.

2.2 Burlington, VT — Fab 9 (200mm)

Specialty RF SOI / SiGe / GaN-power facility acquired from IBM in 2014. The CHIPS Direct Funding Agreement covers Fab 9 modernization (one of the three supported projects). 200mm is the floor process platform for many automotive RF and industrial-power-management customers — strategically protected via specialty processes that 300mm cannot economically replicate.

2.3 Dresden, Germany — Fab 1 (Module 1 + Module 2, 300mm)

Originally acquired from AMD in 2009. 22FDX / 28SLP / 40nm processes, predominantly automotive and industrial customers (European Tier 1 base). EUR-denominated debt facilities ($62M FY25 carrying) tied to this site. EU Chips Act subsidy eligibility is being pursued separately from the US CHIPS Direct Funding Agreement; quantum has not been disclosed.

2.4 Singapore — Fab 7 (Chartered legacy, 300mm) + Fab 3E (200mm) + AMF (200mm SiPh, acquired Nov 2025)

The Singapore footprint just expanded materially with the November 14, 2025 acquisition of Advanced Micro Foundry (AMF) Pte. Ltd. AMF brings a 200mm silicon-photonics line that GFS has integrated into its photonics-foundry portfolio. Per FY25 20-F: “AMF constituted approximately 1% of total assets as of December 31, 2025 and less than 1% of total revenues.” This characterization at “<1% of revenue” implies AMF FY25 revenue contribution was <$68M — likely materially less given partial-year (only ~6 weeks of consolidation).

The AMF integration is a strategically meaningful but financially modest near-term step. It consolidates the 200mm SiPh foundry layer and is most relevant for legacy customer continuity (POET DenseLight, NLM Photonics, smaller fabless photonics firms). The financial impact is back-end-loaded into FY26-27 as customer wafer starts ramp.

2.5 SGD EDB Loan — Singapore Economic Development Board

GFS has a 1.40% SGD-denominated loan from the Singapore Economic Development Board, maturing 2041. FY25 carrying $24M. Combined with “other debt facilities” of $1,098M (largely SGD-denominated), Singapore-related debt is the largest single debt segment on the GFS balance sheet — an explicit reflection of EDB’s role as long-term capacity-incentive partner.

3. CHIPS Act Direct Funding Agreement — $1.575B federal grant

Original agreement (November 2024): Up to $1.5B in planned direct funding under the CHIPS and Science Act. Three projects supported:

  1. Expansion of existing Fab 8 facility (Malta NY)
  2. Construction of a new state-of-the-art fab on the Fab 8 campus (Malta NY greenfield)
  3. Modernization of Fab 9 facility (Burlington VT)

January 2025 add-on: Additional $75M added to the agreement to support a new advanced packaging and testing center at Fab 8.

Total federal commitment: $1.575B

Milestone-based disbursement — funds released only upon achievement of detailed milestones spanning:

  • Capital expenditure thresholds
  • Process technology development / process transfer
  • Facility completion
  • Hiring / workforce development commitments

FY25 progress: First two Fab 8 milestones funded. Remaining ~$1.4B of disbursement is back-loaded.

Restrictive covenants (per FY25 20-F): The agreement contains restrictions on:

  • Certain change-of-control transactions
  • Expansion of manufacturing capacity in certain countries (China carve-out)
  • Joint research or technology licensing in certain countries
  • Dividends and share repurchases

Strategic implication. The CHIPS covenants on dividends/share repurchases likely constrained the timing of the $500M February 2026 buyback authorization (which had to be designed within a 12-month window and explicitly not interfere with grant disbursement). This is one likely reason GFS waited until 2026 to authorize a buyback rather than initiating one in 2024 when the company first turned solidly cash-generative.

4. State of New York Agreement — $570M

Layered atop the federal Direct Funding Agreement. New York State commitment of $570M to support Fab 8 projects, predominantly tied to:

  • Job-creation commitments
  • Workforce development
  • Local infrastructure upgrades

Combined federal + NY support: $1.575B + $570M = $2.145B of subsidy commitment for the Malta + Burlington capacity expansion. Against a multi-year capex commitment likely in the $3–5B range over 2025-2028 ⚠, government grants are offsetting ~50–70% of net incremental capex — economically transforming the capacity buildout from “burn cash” to “subsidized investment.”

5. AMITC tax credit — enhanced from 25% to 35% in 2026

The Advanced Manufacturing Investment Tax Credit (AMITC) under the CHIPS and Science Act provides a federal tax credit for qualifying advanced semiconductor manufacturing capex. The original credit was 25% of qualified investment.

OBBBA (One Big Beautiful Bill Act, signed July 2025): Increased the AMITC from 25% → 35%, beginning tax year 2026.

Direct verbatim from FY25 20-F: “In July 2025, the One Big Beautiful Bill Act ( OBBBA ) was signed into U.S. law. The OBBBA contained significant tax legislation which will impact the Company, including an increase to the AMITC under the CHIPS Act from 25% to 35%, beginning in tax year 2026.”

Impact on GFS:

  • For every $100M of AMITC-eligible capex in 2026+, GFS earns a $35M federal tax credit (vs. $25M previously)
  • The credit is treated by GFS as a reduction of capex on the balance sheet under IFRS (functions as a partial offset to PP&E carrying value)
  • Per FY25 20-F MD&A: “In 2025, we received… $7 million of increased interest income related to an AMITC refund” — implying GFS already received an AMITC-related cash inflow in FY25

OBBBA additionally:

  • Allows immediate deduction of certain R&D costs (rather than capitalize-and-amortize)
  • Expands 100% accelerated depreciation for qualified property placed in service 2025+
  • Modifies §163(j) interest-deduction limitations

Read. The AMITC enhancement from 25% → 35% is one of the most material tax-policy tailwinds for GFS in the 2026-2030 capex cycle. Combined with CHIPS Direct Funding ($1.575B) and NY state ($570M), the effective government contribution to GFS’s Malta/Burlington capacity buildout is probably in the 50–70% range — making the unit-economics of new GFS capacity in the US dramatically more favorable than for competitors building greenfield without these supports.

6. Forward capex profile (FY26-FY28 estimate)

Without explicit guidance from GFS on multi-year capex (the company guides only to next quarter), the analyst profile is anchored on:

  • Q1’26 IFRS opex guide $272M → implies opex / revenue ~17% sustained
  • FY25 capex $722M / revenue $6,791M = 10.6% capex intensity
  • FY24 capex $625M / revenue $6,750M = 9.3% capex intensity (trough)

Analyst FY26 capex estimate: $900M – $1,100M ⚠ — reflecting:

  • CHIPS milestone achievement (mid-cycle disbursement)
  • NY state milestone achievement
  • Continued Fab 8 expansion buildout
  • New advanced-packaging facility ramp
  • AMF integration capex (modest ~$30-50M)
  • Photonics-line capacity for hyperscaler co-packaged optics demand

Analyst FY27 capex estimate: $1,100M – $1,400M ⚠ — assumes greenfield Fab 8 second-fab construction reaches active spend, partially offset by AMITC 35% credit + remaining CHIPS milestones.

Capex intensity converging to ~13–16% over FY26-FY28 vs. FY25’s 10.6% — consistent with management commentary that the company has “high costs that are fixed or difficult to reduce in the short term.” Watch quarterly capex against the $722M FY25 base; sustained quarterly capex >$250M signals the new-capacity-buildout cycle is in its expansion phase.

7. Open items / backfill queue

  1. Multi-year capex guidance — GFS does not guide multi-year capex publicly. Triangulation from sell-side desk research is required for FY26+ projections.
  2. CHIPS milestone schedule — original DOC press release (commerce.gov, 2024-11-20) specifies milestones; FY25 20-F confirms only “first two milestones” achieved in 2025. Next milestones not publicly enumerated.
  3. Capex by fab — not disclosed publicly. GFS does not disaggregate capex below the consolidated cash-flow line.
  4. AMITC current-year claim amount — implied $7M refund inflow in FY25, but the 25% → 35% step-up could materially change the forward AMITC inflow profile. Requires Q1-Q4 2026 6-K disclosure tracking.

Sources

  • FY2025 20-F, acc. 0001709048-26-000022, filed 2026-02-27 — SEC EDGAR — primary source for capex history, CHIPS Direct Funding Agreement, NY State Agreement, AMITC commentary, OBBBA tax legislation impact.
  • U.S. Department of Commerce CHIPS Act press release, 2024-11-20 — commerce.gov — original $1.5B Direct Funding announcement.
  • One Big Beautiful Bill Act (OBBBA), signed July 2025 — public law text (referenced in FY25 20-F MD&A).

Cross-references